Suppr超能文献

脏层胸膜侵犯对非小细胞肺癌患者生存的影响。

Impact of visceral pleural invasion on the survival of patients with non-small cell lung cancer.

机构信息

Division of Thoracic Surgery, Department of Surgery, Tokyo Medical University, Japan.

出版信息

Lung Cancer. 2012 Nov;78(2):153-60. doi: 10.1016/j.lungcan.2012.08.004. Epub 2012 Sep 1.

Abstract

BACKGROUND

In this study, we investigated visceral pleural invasion (VPI) as a poor prognostic factor in patients with non-small cell lung cancer (NSCLC) according to the 7th edition of the TNM classification.

METHODS

Between January 2000 and December 2007, 886 consecutive patients with pathological T1a-T2b NSCLC underwent complete resection with systematic lymph node dissection in Tokyo Medical University. We statistically analyzed the association between VPI and clinicopathologic factors, or clinical outcomes.

RESULTS

The 5-year overall survival (OS) rates of the pl0, pl1, and pl2 patients were 80.8%, 63.7%, and 49.6%, respectively, with significant differences between pl0 and pl1 (p=0.002), pl1 and pl2 (p=0.03). Thus, the pl1 and pl2 patient groups were defined as patients with VPI. VPI was found to be a significant independent prognostic factor by multivariate survival analysis (p=0.0002). In patients with tumors ≤3 cm, especially with tumors ≤2 cm, VPI was significantly associated with an increased rate of lymph node metastasis, compared with non-VPI (p=0.0003 and p=0.015, respectively). Analysis of the OS of patients stratified by tumor size (≤3 cm, 3.1-5 cm, 5.1-7 cm) and VPI status showed that in any nodal status, patients with 3.1-5 cm/VPI tumors had significantly worse survival than patients with ≤3 cm/VPI tumors (p=0.019) and patients with 3.1-5 cm/non-VPI tumors (p=0.001). On the other hand, there was no significant difference in the OS between patients with 3.1-5 cm/VPI tumors and patients with 5.1-7 cm tumors regardless of lymph node metastasis (T2b tumors). Similar relationships were observed among these groups with N0 disease.

CONCLUSION

We identified the presence of VPI as an independent poor prognostic factor in patients with NSCLC of ≤7 cm. Tumors 3.1-5cm with VPI should be upstaged to T2b tumors in the future in the TNM classification of the Union of International Cancer Control staging system. In addition, the surgical strategy involving more extensive lymph node dissection for patients with ≤3 cm/VPI tumors, especially ≤2 cm/VPI, is warranted owing to more frequent lymph node metastasis.

摘要

背景

在本研究中,我们根据第 7 版 TNM 分期,将内脏胸膜侵犯(VPI)作为非小细胞肺癌(NSCLC)患者的不良预后因素进行了研究。

方法

2000 年 1 月至 2007 年 12 月,东京医科大学对 886 例经病理证实的 T1a-T2b NSCLC 患者行完全切除术并系统淋巴结清扫。我们对 VPI 与临床病理因素或临床结局之间的关系进行了统计学分析。

结果

pl0、pl1 和 pl2 患者的 5 年总生存率(OS)分别为 80.8%、63.7%和 49.6%,pl0 与 pl1 之间(p=0.002)、pl1 与 pl2 之间(p=0.03)差异有统计学意义。因此,将 pl1 和 pl2 患者定义为存在 VPI 的患者。多变量生存分析显示,VPI 是一个显著的独立预后因素(p=0.0002)。在肿瘤直径≤3cm 的患者中,特别是肿瘤直径≤2cm 的患者中,与非 VPI 患者相比,VPI 与更高的淋巴结转移率显著相关(p=0.0003 和 p=0.015)。对按肿瘤大小(≤3cm、3.1-5cm、5.1-7cm)和 VPI 状态分层的患者的 OS 进行分析表明,在任何淋巴结状态下,肿瘤直径 3.1-5cm/VPI 患者的生存情况明显差于肿瘤直径≤3cm/VPI 患者(p=0.019)和肿瘤直径 3.1-5cm/非 VPI 患者(p=0.001)。另一方面,无论淋巴结转移情况如何,肿瘤直径 3.1-5cm/VPI 患者与肿瘤直径 5.1-7cm 患者的 OS 之间无显著差异(T2b 肿瘤)。在 N0 疾病的这些组中也观察到了相似的关系。

结论

我们发现 VPI 的存在是非小细胞肺癌患者的独立不良预后因素,肿瘤直径≤7cm。在未来的 UICC 分期的 TNM 分类中,直径 3.1-5cm 且存在 VPI 的肿瘤应升级为 T2b 肿瘤。此外,对于肿瘤直径≤3cm/VPI 患者,尤其是肿瘤直径≤2cm/VPI 患者,由于淋巴结转移更为频繁,需要进行更广泛的淋巴结清扫的手术策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验